AUTHORS
Aaron T. Gerds, MD, MS, Angela (Qi) Fan, MSPH, MPP2, Michelle Jerry, MS3, Alicia Cerretani, PharmD4, Anh Thu Tran, PharmD5, Luis Hernandez, PhD, MPH, MSc6
AFFILIATIONS
1 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
2 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
3 Merative, Ann Arbor, Michigan, United States
4 Takeda Pharmaceuticals America, Inc., Cambridge, Massachusetts, United States
5 Merative, Ann Arbor, Michigan, United States
6 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
ABSTRACT
Introduction: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells resulting in increased blood viscosity and elevated hematocrit (HCT). Guideline-aligned management includes phlebotomy (PHL) and/or cytoreductive therapy (e.g., hydroxyurea [HU], ruxolitinib, interferons) to reduce red blood cell production and maintain HCT <45%, a threshold associated with a lower risk of thromboembolic events (TE) compared with HCT ≥45%. Because commercially insured and Medicare populations differ in age and comorbidity profiles and PV is typically diagnosed around age 60, this study evaluates payer-stratified treatment profiles, HCT control, clinical outcomes, and post-TE healthcare costs among patients with PV receiving guideline-aligned treatments in the United States.
Methods: Commercially- and Medicare-insured patients with ≥1 claim with PV diagnosis (ICD-9: 238.4; ICD-10: D45) and ≥1 claim for PV treatment during 1/1/2011-12/31/2022 were identified in the MarketScan Commercial and Medicare Databases, respectively. The earliest PV treatment date was the index date. Patients were required to have continuous enrollment (6 months pre-index [baseline period] and ≥12 months post-index [follow-up period]) and no evidence of baseline disease progression (myelofibrosis, acute myeloid leukemia, or myelodysplastic syndrome). Treatment patterns and burdensome treatment were reported during the first 12 months of follow-up. HCT control and clinical outcomes (incident TE, incident iron deficiency anemia, and disease progression) were reported during the full follow-up. Burdensome treatment was defined as the use of high-dose HU (defined as ≥1000 mg/day) or frequent PHL (defined as ≥3 PHL in the first 6 months or ≥5 PHL in the first 12 months post-index). For patients with a TE and ≥12 months of follow-up post-TE, all-cause costs during the 12-month post-TE period were reported.
Results: The study included 11,311 treated PV patients (N=7,896 [69.8%] commercial; N=3,415 [30.2%] Medicare). Mean age and male proportion were 52.2 years and 77.9% for commercial patients, and 74.5 years and 62.2% for Medicare patients. Common baseline comorbidities included hypertension (commercial: 41.0%; Medicare: 55.1%), hyperlipidemia (28.3%; 35.1%), and diabetes (13.4%; 20.2%). During the first 12 months of follow-up, few patients received ruxolitinib and/or interferons (commercial: 1.9%; Medicare: 2.0%). High-dose HU was used in 8.0% of commercial and 14.3% of Medicare patients and frequent PHL occurred in 42.9% and 33.5%, respectively; and among those who received high-dose HU, many also received frequent PHL (commercial: 24.4%; Medicare: 16.1%). A high percentage of both payer groups was identified with burdensome treatment and/or incident TE (commercial: 50.8%; Medicare: 50.9%). During the full follow-up period (mean ~3.6 years), 10.5% of commercial patients had an incident TE, 2.9% had disease progression, and 7.9% had incident iron deficiency anemia; for Medicare patients, these rates were higher at 26.5%, 8.0%, and 13.4%, respectively. Among PV patients with a TE and 12 months of data post-TE (N=574 commercial; N=585 Medicare), 12-month post-TE all-cause costs were $79,350 and $63,193, respectively. Among PV patients with post-index HCTs (N=737 commercial; N=531 Medicare; mean [median] number of HCTs during follow-up: 9.6 [5.0] and 14.2 [9.0], respectively), 88.9% of commercial and 80.2% of Medicare patients had some or all HCT measurements ≥45%, while a sizeable proportion (commercial: 60.5%; Medicare: 48.4%) had some or all HCT measurements ≥50%. An average HCT ≥45% during follow-up was observed for 72.0% of commercial and 49.9% of Medicare patients.
Conclusion: This real-world study highlights persistent disease burden among treated PV patients in both commercially insured and Medicare populations, despite their differing age and clinical profiles. This burden was characterized by frequent PHL, high-dose HU, disease progression, iron deficiency anemia, inadequate HCT control, and incident TEs alongside their associated costs. These findings suggest that current guideline-aligned treatments may not consistently achieve durable disease control or mitigate clinical and economic outcomes in routine practice, particularly among older patients, indicating a critical need for novel therapeutic options to optimize patient outcomes and alleviate the overall PV burden.
DISCLOSURES
Luis Hernandez, PhD, MPH, MSc: Takeda - Current equity holder in publicly-traded company; Takeda - Current Employment